Login to Your Account

Alteogen transfers tech to China company for biosimilar development

By Haky Moon
Staff Writer

Friday, March 31, 2017

HONG KONG – A deal between South Korean firm Alteogen Inc. and China’s Qilu Pharmaceutical Co. Ltd. to complete development of a biosimilar drug suggests the technology gap between the two countries is closing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription